SEATTLE, WA--(Marketwired - August 28, 2014) -
Atossa Genetics Inc. (NASDAQ: ATOS
) today announced that its subsidiary, The National Reference Laboratory for Breast Health, Inc., or the NRLBH, has entered into an agreement with BioVentive, Inc. for the marketing and promotion of the NRLBH's laboratory services. The NRLBH is a CLIA-registered laboratory in Seattle, Washington that offers anatomic and clinical pathology services as well as molecular-based testing on a nation-wide basis.
Steven Quay, CEO and President of Atossa said, "Although Atossa has distributors for its medical devices, BioVentive will provide critical marketing services for our laboratory, the NRLBH. BioVentive sales personnel are tenured and highly regarded by the medical community and we look forward to them playing a vital role as the NRLBH develops and commercializes its testing services. BioVentive's 85 strong sales force will offer the NRLBH laboratory services throughout the United States."
Brett Nauta, CEO of BioVentive added, "We are extremely pleased to partner with the NRLBH for the marketing of their laboratory services. Their facilities, tests, and scientists are of the highest quality. We ultimately selected NRLBH based on their customer service commitment to physicians and their patients, which is the most important factor when selecting a reference laboratory."
About Atossa Genetics
Atossa Genetics Inc. is focused on improving breast health through the development of laboratory services, medical devices and therapeutics. The laboratory services are being developed by its subsidiary, the NRLBH. The laboratory services and the Company's medical devices are being developed so they can be used as companions to therapeutics to treat various breast health conditions. For additional information, please visit www.atossagenetics.com.
BioVentive, Inc. provides an experienced sales and marketing team of over 85 women's health sales representatives who bring their sales experience from some of the largest Fortune 100 healthcare organizations across the United States.
Forward-looking statements in this press release are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties detailed from time to time in Atossa's filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time. Those risks and uncertainties include, for example, actions by the FDA, performance of commercial partners, and whether the NRLBH can commercialize its laboratory services in a timely and cost effective manner.